[{"id":"7dbbc938-f2df-43be-869e-296694ec3653","acronym":"","url":"https://clinicaltrials.gov/study/NCT02593227","created_at":"2021-01-18T12:35:08.510Z","updated_at":"2024-07-02T16:36:27.756Z","phase":"Phase 2","brief_title":"Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer","source_id_and_acronym":"NCT02593227","lead_sponsor":"Marker Therapeutics, Inc.","biomarkers":" HER-2 • FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["HER-2 • FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • TPIV200 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 07/15/2021","study_completion_date":" 07/15/2021","last_update_posted":"2021-07-19"}]